{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:24:38Z","timestamp":1790861078569,"version":"4.1.0"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A number of neuropeptides, including pituitary adenylate cyclase-activating polypeptide (PACAP), play an important role in the pathophysiology of migraine. Infusions of PACAP in patients with migraine can provoke migraine attacks. A placebo-controlled study with a monoclonal antibody directed against the PACAP-receptor failed to show efficacy. In a small, short, proof-of-concept study, a monoclonal antibody directed against PACAP (Lu AG09222) showed efficacy in reducing monthly migraine days compared to placebo but failed for the end point 50% reduction in migraine days. The ongoing PROCEED study, a double-blind, placebo-controlled, dose-finding study investigating four different doses of Lu AG09222 versus placebo for migraine prevention, is expected to complete in the second half of 2025.<\/jats:p>","DOI":"10.1093\/brain\/awaf131","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:14:46Z","timestamp":1748564086000},"page":"2646-2649","source":"Crossref","is-referenced-by-count":7,"title":["PACAP and migraine"],"prefix":"10.1093","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6556-8612","authenticated-orcid":false,"given":"Hans Christoph","family":"Diener","sequence":"first","affiliation":[{"name":"Department of Neuroepidemiology, Institute for Medical Informatics, Biometry and Epidemiology (IMIBE), Faculty of Medicine, University Duisburg-Essen , Essen 45147 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"2025080112521585400_awaf131-B1","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","article-title":"Global, regional, and national burden of disorders affecting the nervous system, 1990\u20132021: A systematic analysis for the global burden of disease study 2021","volume":"23","author":"GBD 2021 Nervous System Disorders Collaborators","year":"2024","journal-title":"Lancet Neurol"},{"issue":"9","key":"2025080112521585400_awaf131-B2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241269735","article-title":"International headache society global practice recommendations for preventive pharmacological treatment of migraine","volume":"44","author":"Puledda","year":"2024","journal-title":"Cephalalgia"},{"key":"2025080112521585400_awaf131-B3","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0333102410364677","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial","volume":"30","author":"Diener","year":"2010","journal-title":"Cephalalgia"},{"key":"2025080112521585400_awaf131-B4","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/0333102410364676","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial","volume":"30","author":"Aurora","year":"2010","journal-title":"Cephalalgia"},{"key":"2025080112521585400_awaf131-B5","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/ana.410280213","article-title":"Vasoactive peptide release in the extracerebral circulation of humans during migraine headache","volume":"28","author":"Goadsby","year":"1990","journal-title":"Ann Neurol"},{"issue":"Suppl 11","key":"2025080112521585400_awaf131-B6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0333102491011S1102","article-title":"Sumatriptan reverses the changes in calcitonin gene-related peptide seen in the headache phase of migraine","volume":"11","author":"Goadsby","year":"1991","journal-title":"Cephalalgia"},{"issue":"4","key":"2025080112521585400_awaf131-B7","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231159366","article-title":"Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials","volume":"43","author":"Haghdoost","year":"2023","journal-title":"Cephalalgia"},{"key":"2025080112521585400_awaf131-B8","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/acn3.52119","article-title":"Pituitary cyclase-activating polypeptide targeted treatments for the treatment of primary headache disorders","volume":"11","author":"Karsan","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"2025080112521585400_awaf131-B9","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S0022-3565(25)39457-7","article-title":"Passage of pituitary adenylate cyclase activating polypeptide1-27 and pituitary adenylate cyclase activating polypeptide1\u201338 across the blood-brain barrier","volume":"267","author":"Banks","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"2025080112521585400_awaf131-B10","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/acn3.113","article-title":"Pituitary adenylate cyclase activating polypeptide and migraine","volume":"1","author":"Zagami","year":"2014","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"2025080112521585400_awaf131-B11","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/brain\/awn307","article-title":"PACAP38 induces migraine-like attacks in patients with migraine without aura","volume":"132","author":"Schytz","year":"2009","journal-title":"Brain"},{"key":"2025080112521585400_awaf131-B12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0333102419864507","article-title":"PACAP27 induces migraine-like attacks in migraine patients","volume":"40","author":"Ghanizada","year":"2020","journal-title":"Cephalalgia"},{"key":"2025080112521585400_awaf131-B13","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1097\/j.pain.0000000000000702","article-title":"Premonitory and nonheadache symptoms induced by CGRP and PACAP38 in patients with migraine","volume":"157","author":"Guo","year":"2016","journal-title":"Pain"},{"issue":"3","key":"2025080112521585400_awaf131-B14","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/brain\/awt369","article-title":"Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38","volume":"137","author":"Amin","year":"2014","journal-title":"Brain"},{"key":"2025080112521585400_awaf131-B15","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s10194-018-0893-8","article-title":"PACAP38 and PAC(1) receptor blockade: A new target for headache?","volume":"19","author":"Rubio-Beltr\u00e1n","year":"2018","journal-title":"J Headache Pain"},{"key":"2025080112521585400_awaf131-B16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/0333102420970889","article-title":"A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention","volume":"41","author":"Ashina","year":"2021","journal-title":"Cephalalgia"},{"key":"2025080112521585400_awaf131-B17","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa2314577","article-title":"A monoclonal antibody to PACAP for migraine prevention","volume":"391","author":"Ashina","year":"2024","journal-title":"Ne Engl J Med"},{"key":"2025080112521585400_awaf131-B18","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41582-024-01011-4","article-title":"Pituitary adenylate cyclase-activating polypeptide signalling as a therapeutic target in migraine","volume":"20","author":"Ashina","year":"2024","journal-title":"Nat Rev Neurol"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/brain\/advance-article-pdf\/doi\/10.1093\/brain\/awaf131\/63401643\/awaf131.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/148\/8\/2646\/63401643\/awaf131.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/148\/8\/2646\/63401643\/awaf131.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T16:52:27Z","timestamp":1754067147000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/148\/8\/2646\/8153082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":18,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,5,30]]},"published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awaf131","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,5,30]]}}}